Table 4. Comparison of antimicrobial susceptibility between Escherichia coli and Klebsiella pneumoniae .

	Total (n = 329)			Community-onset APN (n = 219)			Healthcare-associated APN (n = 110)
	E. coli (n = 258) N (%)	K. pneumoniae (n = 71) N (%)	P value	E. coli (n = 194) N (%)	K. pneumoniae (n = 25) N (%)	P value	E. coli (n = 64) N (%)	K. pneumoniae (n = 46) N (%)	P value
Amikacin	255 (99.2%)	67 (94.4%)	0.021	193 (100.0%)	25 (100.0%)	-	62 (96.9%)	42 (91.3%)	0.234
Amoxicillin/clavulanate	154 (59.9%)	48 (67.6%)	0.239	129 (66.8%)	24 (96.0%)	0.003	25 (39.1%)	24 (52.2%)	0.172
Aztreonam	153 (59.5%)	38 (53.5%)	0.363	137 (71.0%)	23 (92.0%)	0.025	16 (25.0%)	15 (32.6%)	0.382
Cefazolin	140 (54.5%)	36 (50.7%)	0.573	126 (65.3%)	23 (92.0%)	0.007	14 (21.9%)	13 (28.3%)	0.443
Cefotaxime	148 (57.6%)	38 (53.5%)	0.540	133 (68.9%)	23 (92.0%)	0.025	15 (23.4%)	15 (32.6%)	0.287
Cefepime	153 (59.5%)	39 (54.9%)	0.486	137 (71.0%)	23 (92.0%)	0.025	16 (25.0%)	16 (34.8%)	0.265
Ciprofloxacin	144 (56.0%)	50 (70.4%)	0.029	130 (67.4%)	24 (96.0%)	0.003	14 (21.9%)	26 (56.5%)	0.001
Gentamicin	170 (66.1%)	57 (80.3%)	0.022	139 (72.0%)	22 (88.0%)	0.087	31 (48.4%)	35 (76.1%)	0.004
Piperacillin/tazobactam	232 (90.3%)	53 (74.6%)	0.001	180 (93.3%)	24 (96.0%)	0.999	52 (81.2%)	29 (63.0%)	0.033
Tigecycline	257 (100.0%)	64 (90.1%)	0.001	193 (100.0%)	24 (96.0%)	0.115	64 (100.0%)	40 (87.0%)	0.004
TMP/SMX	155 (60.3%)	46 (64.8%)	0.493	127 (65.8%)	22 (88.0%)	0.025	28 (43.8%)	24 (52.2%)	0.383
ESBL positivity	104 (40.5%)	32 (45.1%)	0.486	56 (29.0%)	2 (8.0%)	0.025	48 (75.0%)	30 (65.2%)	0.265

APN, acute pyelonephritis; TMP/SMX, trimethoprim/sulfamethoxazole; ESBL, extended-spectrum β-lactamase.